TuHURA Biosciences, Inc. Common Stock (HURA) Stock
NASDAQ · HURA
2.10
Fundamentals
Market cap
$133.83M
Price / Earnings ratio
-4.3x
Price / Sales ratio
N/A
Price / Book ratio
7.2x
Return on assets
-1.1%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
SectorHealthcare
IndustryBiotechnology
Employees22
CEODr. James A. Bianco M.D.
IPO DateFeb 22, 2013
HeadquartersTampa, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Bianco M.D. | President, CEO & Director | 1957 |
| Mr. Dan Dearborn CPA | Executive VP of Finance & CFO | 1967 |
| Mr. Michael Lawman | Co-Founder | — |
| Ms. Patricia Lawman | Co-Founder | — |
| Mr. Michael Krsulich | Head of Quality Assurance | — |
| Ms. Amanda Garofalo | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Market cap$133.83M
Price-to-sales ratioN/A
Price-to-book value7.20
Price-earnings ratio-4.30
Return on Equity-154.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.54
Income Statement
Average volume191,666
EBITDA$-30.19M
1 year high (52w)$3.43
1 year low (52w)$0.41
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



